Introduction
The publication of the first Mycobacterium tuberculosis genome sequence in 1998 heralded a new era in tuberculosis (TB) research. 1 The bacterium was found to have a relatively small circular genome of approximately 4.5 million base pairs and was estimated to have around 4000 potential genes. Sequencing of the M. tuberculosis H37Rv reference strain was soon followed by other strains, and expectations were high that mechanisms of pathogenesis and virulence were about to be revealed that would enable the development of novel drugs and improved vaccines to assist in TB control. 2, 3 However, the anticipated advances have been slow to materialize and such work continues, accompanied by the realization of the sophistication of M. tuberculosis as a highly successful human pathogen.
The early genomes were deciphered using various cloning and shotgun sequencing approaches, followed by assembly and annotation with an assortment of analytical tools -a painstaking process with each genome taking years to complete. Advances in technology over the past 15 years have greatly reduced the complexity, cost, and time of sequencing. Thousands of M. tuberculosis strains have since been sequenced, contributing to studies on evolution, transmission, and drug resistance. [4] [5] [6] [7] [8] [9] [10] Several Web-based tools have been developed to assist TB sequence analysis, and software is now freely available for rapid genotypic analysis and the identification of drug resistance-associated mutations. [11] [12] [13] [14] [15] Next-generation sequencing (NGS) is already used in clinical practice for characterizing cancers and hereditary diseases. It may also be used to assist TB case management by detecting resistance to anti-TB drugs. [16] [17] [18] However, the quality of the DNA template is critical for successful whole genome sequencing (WGS), and M. tuberculosis presents considerable technical challenges in this respect. Firstly, the scarcity of bacilli in clinical samples limits the availability of M. tuberculosis genomic DNA (gDNA). Secondly, the remarkable hardiness of the lipid-rich M. tuberculosis cell wall makes disruption of the M. tuberculosis bacterium difficult and can affect the quality and the yield of gDNA. In addition, the M. tuberculosis genome itself is unusually robust, with a guanine/ cytosine average content of 65% across the genome, and with some regions exceeding 80%. 1 Thus careful consideration must be given to the choice of sample, bacterial lysis, DNA extraction methodology, library preparation, and sequencing platform if M. tuberculosis sequencing is to enter routine clinical practice. 19 This article explores sample collection and processing as crucial factors for WGS and NGS analysis of patient-derived M. tuberculosis. Although some questions remain unanswered, advice is offered on current best practices and pitfalls to avoid.
Next-generation sequencing platforms
NGS technologies analyse whole genomes without recourse to cloning, as was previously required for Sanger sequencing. High throughput platforms have been developed that can analyse millions of DNA fragments in parallel, and sequencing of bacterial genomes that previously took years to complete can now be achieved in hours. Sophisticated labelling systems allow multiplexing, where multiple samples are combined within a single run, greatly reducing costs. The early NGS platforms required specialized laboratories and highly trained personnel, but newer bench-top instruments suitable for clinical laboratories are now available. In addition to WGS, targeted sequencing, where multiple targets are amplified and sequenced in parallel, offers a rapid detection of resistance, albeit on a limited scale compared to whole genome approaches. 17, 20 Several NGS systems are commercially available, providing a range of platforms to choose from, some of which have gone through regulatory registration and clearance. Two NGS systems have been used to detect mutations associated with M. tuberculosis drug resistance. 21 Illumina sequencing (Illumina, San Diego, CA, USA) is based on reversible dye-terminators. 22 First a library is prepared whereby pure DNA is chopped into smaller fragments that are modified prior to amplification on a specialized chip holding hundreds of thousands of oligonucleotides. New fragments are built one nucleotide at a time, with fluorescent tags indicating which nucleotide has been incorporated. Sequential rounds of nucleotide additions build a new strand of DNA, with thousands of positions throughout the genome being sequenced at the same time in a process called massive parallel sequencing. The result is millions of short DNA fragments replicating the entire genome, with multiple fragments covering each stretch of gDNA. In most cases fragments are aligned and assembled by computation against a predetermined reference genome, thus allowing for the identification of polymorphisms. The depth of coverage (number of fragments that represents a specific nucleotide) is an indication of sequencing quality for each nucleotide sequenced, because if hundreds of fragments give the same signal for a specific position there is high confidence in the specific nucleotide call. Depth of coverage varies across genomes and is adversely affected by regions of high GC content and repetitive elements. Typically, when calling drug resistance mutations, coverage of at least 10-fold is required. However, other studies suggest at least 30-fold coverage is needed, else the result is considered of low confidence. 19 Ion Torrent or Ion semiconductor sequencing (Ion Torrent Inc., USA, marketed by Thermo Fisher Scientific) uses different chemistry to monitor nucleotides incorporated during the creation by polymerization reaction of the new strand of DNA. 23 Sequencing is performed on semiconductor chips that detect changes in pH caused by the release of H + ions during the polymerization of DNA and incorporation of deoxyribonucleoside triphosphate (dNTP). dNTPs are added sequentially, with washing between each step to remove unbound nucleotide molecules. As with Illumina sequencing, assembly by computation and comparison with reference genomes provides a readout of the whole genome and identifies polymorphisms. Labelling dyes and optical detection are not employed in this platform, a factor that the manufacturer claims increases the speed of sequencing and reduces running costs. Ion Torrent sequencing has been used successfully to detect mutations associated with M. tuberculosis drug resistance. 16, 21 PacBio sequencing, or single molecule real-time sequencing (Pacific Biosciences, USA), is primarily being utilized as a research tool. 24 Rather than short fragments, this technology generates long strands of DNA and it is possible to assemble whole bacterial genomes from a single reaction. Assembly problems for repetitive regions encountered with short-read sequencing methods are overcome, for example the M. tuberculosis PE and PPE gene families, which are often excluded from Illumina sequencing data analysis. The technology may also be used to investigate DNA methylation, DNA damage, and other epigenetic information. PacBio sequencing is rapid, but has a limited capacity to multiplex, which translates to a moderate throughput. A drawback when considering clinical applications is the requirement for large amounts of pure high molecular mass gDNA, which for M. tuberculosis necessitates lengthy culture and extraction processes.
The MinION sequencing platform (Oxford Nanopore Technologies, UK) is a rapid technology with a portable sequencing instrument that also offers relatively long read lengths. 25 It was recently shown to detect antibiotic resistance genes of Escherichia coli in DNA purified from urine following processing to remove contaminating human DNA, with results available in approximately 4 h. 26 However, successful sequencing of the M. tuberculosis genome with this platform has not yet been reported.
The choice of sequencing strategy is influenced by the reasoning for sequencing. Identifying novel polymorphisms of biological significance ideally requires a depth of coverage of at least 100fold, and for discovering rare polymorphisms up to a 1000-fold coverage may be preferred. Similarly, to investigate transmission chains and differentiate between closely related bacteria with confidence requires high coverage. Lower coverage (20-to 30-fold) may be sufficient to observe specific well-defined single nucleotide polymorphisms (SNPs). Thus, while high quality DNA with few strand breaks may be crucial for some research applications, DNA of lower quality may be tolerated when looking for known SNPs associated with drug resistance. For sequencing to be optimally effective for managing patients with drug-resistant TB, results should be available in days rather than weeks and ideally sequencing should be performed directly from primary clinical specimens. It should be noted, however, that when dealing with patient samples, mixed infections (more than one M. tuberculosis strain) and heteroresistance (more than one polymorphism at the same point) may require special consideration, and higher depth of reads are desirable. There is as yet no consensus on the depth of coverage required for NGS drug resistance screening for M. tuberculosis.
Sputum collection and processing
The sample of choice for the diagnosis of pulmonary TB is expectorated sputum, which is subjected to analysis by smear microscopy, culture, or diagnostic PCR. Currently WGS is performed following the isolation and culture of the bacteria, which may take weeks; thus, it would be of considerable advantage to sequence directly from the clinical sample. Sputum may be obtained spontaneously (by instructing the patient to cough 27 ) or by induction following the inhalation of a fine spray of saline. 28 M. tuberculosis is an aerosol-spread pathogen and as such stringent safety precautions must be implemented whenever live bacteria may be present. This includes during sample collection. M. tuberculosis bacilli are rarely found in saliva, and the quality of specimens received should be monitored to avoid processing of substandard samples. 29 The number of M. tuberculosis bacilli in a TB-positive sputum sample may vary between a handful to millions. 30 In the case of smear-positive sputum, it is assumed that the bacillary load is at least 10 000 bacilli per millilitre of sputum.
WGS and targeted NGS directly from sputum has been demonstrated, but to date no systematic investigations of sample preparation procedures with an output of providing WGS or targeted NGS quality gDNA suitable for detailed analysis of drug resistance-associated mutations has been reported (see Table 1 ). The quality of sequence data obtained (coverage and depth of reads) is dependent on the purity and integrity of DNA submitted. Sputum is a complex matrix containing mucus, human cells, cell debris, various bacteria and viruses, and sometimes blood and pus. It is often viscous with semi-solid lumps, which require thinning to release the bacteria. Three approaches are possible: heating, chemical treatment, and physical disruption, such as vortexing with 3-4-mm diameter glass beads. 31 However, all of these approaches risk damaging the bacterial cell wall, permitting direct exposure of the gDNA to extreme conditions, as well as the potential for the release of gDNA, which may be lost during subsequent washing and concentration steps. In addition, traditional techniques such as bead-beating and sonication may fragment the DNA and are not recommended for sequencing protocols where DNA of high integrity is needed. 32 In order to amplify the number of M. tuberculosis bacteria from the sample, clinical specimens are cultured. Culture typically requires 3-4 weeks, but may take longer since some M. tuberculosis may be associated with a slower growing phenotype, particularly strains with high-grade drug resistance. It may be possible to sequence from early cultures, where the number of M. tuberculosis bacilli has been enriched, but prior to microbiological culture positivity. In such cases the efficiency of WGS may be influenced by the sample processing required for culture. The slow growth rate of M. tuberculosis makes it vulnerable to overgrowth by other microorganisms; to prevent this unwanted contamination, clinical specimens are treated with sodium hydroxide or acid to preferentially kill the unwanted microorganisms. 30 Due to their robust cell walls, some M. tuberculosis bacilli survive this process and following neutralization and concentration by centrifugation the samples are placed in broth or solid media for culturing. 33 Other reagents that assist sputum processing are N-acetyl-Lcysteine, which disrupts disulfide bonds, 34 and detergents such as sodium laurylsulphate. 30 Unfortunately, not all of the M. tuberculosis bacteria survive the decontamination process and considerable losses may occur at this stage if the process is not well controlled. 35 In addition, overgrowth by contaminants or no growth due to harsh sample pre-treatment may require the entire process to be repeated.
Additional methods and adjuncts have been used post-culture to enhance the isolation of M. tuberculosis gDNA. Bactericidal reagents such as isopropanol can assist by their ability to denature proteins and damage bacterial cell walls. Similarly, guanidine thiocyanate may be used where gDNA released is captured using activated silica. 36 Further purification and removal of proteins can be effected by phenol and chloroform extraction when, at the appropriate pH, DNA will partition into the aqueous layer. 37 It should be noted that bleach (sodium hypochlorite) should not be used, as although it will effectively thin sputum, it is highly detrimental to DNA. 38 An extraction procedure optimized for maximum sensitivity has been developed by scientists investigating M. tuberculosis in archaeological specimens. 39 This incorporates enzyme digestion with Proteinase K and extended incubation in guanidium thiocyanate for up to 3 days at 56 8C. N-phenacylthiazolium bromide (PTB) is then used to cleave covalent cross-links to enable strand separation and amplification. Although effective for ancient samples, the technique also recommends using bead-beating and freeze/thaw steps that are less suitable for an analysis that requires DNA of high integrity.
Enrichment methods
A particular challenge for NGS sequencing from sputum is the presence of low numbers of bacteria amongst high levels of other materials. This includes large amounts of DNA of human origin and from other bacteria, which will react with sequencing reagents and may quench the reaction by out-competing the M. tuberculosis DNA. To enhance sensitivity, it is necessary to increase the proportion of M. tuberculosis DNA by a process of enrichment. However, any enrichment technique may run the risk of selection bias, which can alter the results. A potential way to reduce levels of human DNA is enzymatic degradation following differential lysis, in which the human cells are lysed but the bacilli remain intact. 40 Doughty et al. evaluated water-induced osmotic lysis of human cells in N-acetyl-L-cysteine liquefied sputum. Following treatment with DNAase the samples were washed and heat-treated to remove the enzyme before the extraction of M. tuberculosis DNA was initiated. 41 Samples were sequenced using a shotgun approach, but success was limited. Although characteristic M. tuberculosis signals were identified, the depth of coverage obtained was insufficient for the detection of drug resistance-associated mutations with a high confidence of the nucleotide call. An alternative approach is to capture either the bacteria or the bacterial DNA and remove them from the sample matrix. A simple approach is preferential binding to magnetic beads, and products are commercially available that utilize ligand-coated beads to bind bacteria. 42, 43 A more sophisticated approach involves specific pulldown of M. tuberculosis DNA using complementary oligonucleotides. Brown et al. succeeded in sequencing M. tuberculosis from 24 smear-positive sputum specimens using a number of 120mer RNA baits that complement and span the M. tuberculosis genome. 18 The baits were labelled with biotin, thus enabling library preparation using the SureSelect XT system (Agilent Technologies) followed by Illumina paired-end sequencing. Although successful, the authors point out that the requirement for highly specialized skills and equipment and estimated cost per sample of approximately US$350 may be a disadvantage, therefore other strategies need to be explored. A potential, less expensive approach is whole genome amplification, which has been applied to other bacteria with some success. 44, 45 Whole genome multiple displacement amplification uses small random primers and high-fidelity DNA polymerase (phi29) to amplify large segments of DNA. 46 The technique requires good quality DNA, but its capacity to amplify the GC-rich regions of the M. tuberculosis genome has yet to be reported.
Sequencing from cultured bacteria
DNA extracted from cultured bacteria may be used in genomewide association studies (GWAS) to identify putative resistance mutations. In addition, isolation and culturing of the bacteria from sputum samples serves as an effective enrichment strategy, where sequencing from cultures may provide information of resistance more rapidly than phenotypic testing methods. [47] [48] [49] 59 [ 2 _ T D $ D I F F ] To ensure sequence data of satisfactory quality with sufficient depth of reads, the quality and quantity of the extracted DNA should be checked before samples are submitted for library preparation and sequencing. Simple spectroscopic methods to measure absorption are not adequate as they frequently give misleading results due to small nucleic acids and contaminating chemicals. Quantity should be checked using targeted DNA-specific tests. To examine the integrity of the DNA, a sample should be examined by agarose electrophoresis (see Supplementary Material for further details).
Lessons learned from extracting cultured organisms may assist in the development of sputum processing methods. M. tuberculosis bacilli have a characteristic lipid-rich cell wall that is highly protective of the cell contents. Layers of peptidoglycan (crosslinked for additional stability), lipoglycans, mycolic acids, and large waxes form a robust barrier that must be overcome to allow the release of the gDNA. Methods to break open the cell wall include enzymatic, mechanical, and chemical approaches. 50, 51 Enzymes may be used sequentially, with lysozymes to degrade the cell wall followed by proteinases, combined with solvent extraction to remove extracellular proteins. 52 Mechanical methods including bead-beating, sonication, freeze-fracturing, homogenizing, grinding (frozen samples), and high pressure have also been employed. 50, 52 Kaser et al. reported optimum results using a bead-beater with beads of a small diameter (0.1 mm). 32 Unfortunately, these physical methods risk shearing the gDNA, which may affect sequencing quality. 32, 50, 53 Chemical methods include the use of detergents, and chaotropic agents such as guanidine thiocyanate have also been investigated. 32, 36 Once released and purified, the bacterial DNA is highly vulnerable to degradation from naturally occurring enzymes and should be protected by use of DNAase-free reagents and the addition of metal chelating reagents such as ethylenediaminetetraacetic acid (EDTA). (Note: EDTA may be detrimental to some enzyme-based sequencing reactions.) gDNA may also be damaged by physical and environmental forces such as shearing, UV light, and high temperatures.
A DNA extraction protocol previously developed for restriction fragment length polymorphism (RFLP) analysis has been shown to consistently provide DNA of high molecular weight and sufficient quality for sequencing 54 (see Supplementary Material for full protocol). In this method, cells are heated to 80 8C before cooling and treating with lysozyme. A Proteinase K/detergent solution (sodium dodecyl sulphate) is then added and the solution incubated at 65 8C prior to treatment with cetyl trimethylammonium bromide (CTAB) to precipitate lipoglycans and polysaccharides, 55 thus assisting their removal along with unwanted proteins during organic solvent extraction (chloroform/isoamyl alcohol). This method of DNA purification has been used successfully for M. tuberculosis with the Illumina, Ion Torrent, and PacBio sequencing platforms. However, for use in a clinical laboratory, the DNA extraction method selected should be robust and time-efficient, and some improvement on the above protocol in this respect may expedite the uptake of WGS in a routine laboratory setting.
Conclusions
The emergence of resistance to multiple anti-TB drugs is an urgent public health problem. 56 The World Health Organization recommends at least five effective medicines be used for patients with rifampicin-resistant or multidrug-resistant TB (resistance to at least rifampicin and isoniazid). 57 Poor access to susceptibility tests often results in empiric treatment with a drug regimen that may not be effective if the bacteria have already developed resistance to some, or all of the drugs.
Considerable progress has been made towards determining resistance to anti-TB drugs by WGS, which would enable personalized and optimized treatment for patients. Sequencing should ideally be done directly from clinical samples to prevent the lengthy delays incurred during culture-based phenotypic testing, thus accelerating access to effective treatment. Although new sequencing platforms and analytical software are now available, there is as yet no consensus on the critical issue of sample preparation. The literature is rich with potential techniques and methodologies, but an inclusive systematic review of the topic is lacking. Traditional techniques such as bead-beating and sonication that are used successfully in conjunction with PCR-based detection may not be appropriate for sequencing protocols in which high molecular mass gDNA is required. 32 There have been few attempts to optimize extraction for M. tuberculosis WGS or targeted NGS for detecting mutations that are presumptively associated with drug resistance, and evidence of the impact of extraction tools on sequence quality is currently insufficient.
Whilst other aspects of WGS, such as determining phylogenetic strain lineage, virulence, etc., are essential in understanding the transmission and pathogenesis of TB, it is detecting drug resistance directly from clinical samples that warrants priority. Given the scope of the topic and the urgency of the clinical and public health need, consideration should be given to a coordinated collaborative approach to reduce duplication and fast-track progress. Precedence for such an initiative has previously been established through the creation of the ReSeq TB Consortium by which a comprehensive database of drug resistance-associated mutations is being developed though international collaboration. 58 The TB research community is urged to follow this example and work together to identify methodological algorithms that will allow rapid comprehensive testing for drug resistance by WGS. Accelerated access to effective treatment for patients with multiple and extensively drug-resistant disease would reduce morbidity and mortality, improve patient care and the familial burden, and may also reduce opportunities for transmission. Thus a consolidated approach that is affordable to the regions where drug-resistant TB is endemic, towards the development of standardized, optimized DNA extraction protocols, will benefit both patients and efforts to control this deadly disease. Acknowledgements T.G.C. is supported by the Medical Research Council UK (grant number MR/K000551/1, MR/M01360X/1, MR/N010469/1, MC_PC_15103). SC is funded by the Medical Research Council UK (grant number MR/M01360X/1, MC_PC_15103). K.D. is supported by the EDCTP, South African MRC, and the NIH. The study sponsors had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication.
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